RE: "New treatment approach targets cancer 'Death Star' 07.07.202119 May 2022 08:29
Seems to me that considering the considerable headwinds they faced in actually getting the LFT to market, and the fact the likes of NCYT, ODX, ABDX, BRH etc all faced similar headwinds including none payment that it was always going to be a losing battle. That’s the difference with AVA6000, the MHRA actually gave us the green light ahead of time to proceed to clinic with zero causes for concern. We’re in a totally different situation now. It’s a totally different kind of market; we aren’t competing against inferior imports as we were against innova or a scandal of the PPE sort. If you take the positivity of the Avacta team and the fact the trial is ongoing, it’s clearly going well. If you compare it to the delays with the LFT then you’re comparing two scenarios that are wildly different; we aren’t working on a product that’s being sold into a diminishing market and against a waning public enthusiasm (for testing), we’re developing a treatment for a disease that’ll probably never be gone.
All this requires is patience. And a hobby to help stay distracted while we wait.